	US 12,312,407 B2
	Universal T cells and the method of use thereof
Lingfeng Liu, Seattle, WA (US)
Assigned to ST PHI THERAPEUTICS CO., LTD., Hangzhou (CN)
Filed by ST PHI THERAPEUTICS CO., LTD., Zhejiang (CN)
Filed on Feb. 1, 2021, as Appl. No. 17/164,834.
Claims priority of provisional application 62/968,071, filed on Jan. 30, 2020.
Prior Publication US 2021/0253712 A1, Aug. 19, 2021
Int. Cl. C07K 16/28 (2006.01); C07K 14/005 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01)

CPC C07K 16/2833 (2013.01) [C07K 14/005 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/7056 (2013.01); C07K 14/70578 (2013.01); C07K 16/2809 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C12N 2710/16122 (2013.01)]

20 Claims

1. A chimeric fusion protein comprising a target protein binding moiety comprising an anti-TCRαβ scFv, one or more transmembrane domain of a viral ER-resident glycoprotein and one or more cytoplasmic domain of a viral ER-resident glycoprotein, wherein the viral ER-resident glycoprotein comprises Adenovirus E19.